Oral Oncology: Utilization of Selected Oral Antineoplastic Enzyme Inhibitor Agents
An overview of the utilization and cost for selected oral antineoplastic agents, with discussion regarding oncology in general, as well as the topic of adherence.
Read More
Prescription Utilization of the Oral Anticoagulants
New and forthcoming oral anticoagulants, which do not require prothrombin time monitoring, will offer patients and providers additional therapeutic options.
Read More
Initial Prescription Utilization of the New Hepatitis C Agents
Incivek and Victrelis, approved for Hepatitis C within weeks of each other in May 2011, look to change the way the disease is treated.
Read More